Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.

Atrio JM, Sperling RS, Posada R, Rodriguez Caprio G, Chen KT.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e158-9. doi: 10.1097/QAI.0b013e31829baf03. No abstract available.

PMID:
23970241
2.

Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1287-92. doi: 10.1089/AID.2013.0002. Epub 2013 Jul 19.

3.

Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.

Choe PG, Park WB, Song JS, Kim NH, Song KH, Park SW, Kim HB, Kim NJ, Oh MD.

J Korean Med Sci. 2010 Oct;25(10):1427-30. doi: 10.3346/jkms.2010.25.10.1427. Epub 2010 Sep 17.

4.

Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.

Bissio E, Lopardo GD.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):415-7. doi: 10.1089/AID.2012.0233. Epub 2012 Nov 28. No abstract available.

5.

Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.

Avihingsanon A, Tongkobpetch S, Kerr SJ, Punyawudho B, Suphapeetiporn K, Gorowara M, Ruxrungtham K, Shotelersuk V.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7. doi: 10.1097/QAI.0000000000000540. No abstract available.

PMID:
25622064
6.

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Rodríguez Nóvoa S, Barreiro P, Rendón A, Barrios A, Corral A, Jiménez-Nacher I, González-Lahoz J, Soriano V.

Clin Infect Dis. 2006 Jan 15;42(2):291-5. Epub 2005 Dec 8.

PMID:
16355344
7.

Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary.

Bradbeer C, Ngwenya S, Baker P, George M.

Int J STD AIDS. 2012 Oct;23(10):759. doi: 10.1258/ijsa.2012.012053. No abstract available.

PMID:
23104755
8.

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.

Culley CL, Kiang TK, Gilchrist SE, Ensom MH.

Ann Pharmacother. 2013 Apr;47(4):561-72. doi: 10.1345/aph.1R550. Epub 2013 Apr 2. Review.

PMID:
23548653
9.

Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.

Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, Treluyer JM, Herinomenzanahary E, Ferreira C, Peytavin G.

Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):18-21. doi: 10.1016/j.ejogrb.2011.02.005. Epub 2011 Apr 13.

PMID:
21492993
10.

Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.

East J, Blanton LS.

Antimicrob Agents Chemother. 2012 Feb;56(2):1081-3. doi: 10.1128/AAC.05806-11. Epub 2011 Nov 28.

11.

[Adverse effects of atazanavir].

Palacios R, González M, Ruiz J, Santos J.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:41-4. doi: 10.1016/S0213-005X(08)76619-9. Review. Spanish.

PMID:
20116616
12.

[Utility of atazanavir in special populations].

Antela López A.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:49-54. doi: 10.1016/S0213-005X(08)76621-7. Review. Spanish.

PMID:
20116618
13.

[Pharmacology, pharmacokinetic features and interactions of atazanavir].

López-Cortés LF.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8. Review. Spanish.

PMID:
20116610
14.

Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.

Esker S, Albano J, Uy J, Arikan D, Jimenez-Exposito MJ, Seekins D, Tilson H.

AIDS Patient Care STDS. 2012 Jun;26(6):307-11. doi: 10.1089/apc.2011.0444. Epub 2012 Mar 9. No abstract available.

PMID:
22404239
15.

Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.

Laprise C, Baril JG, Dufresne S, Trottier H.

AIDS Patient Care STDS. 2013 Jul;27(7):378-86. doi: 10.1089/apc.2013.0009.

16.

FDA notifications. Reyataz is approved for HIV treatment.

[No authors listed]

AIDS Alert. 2003 Sep;18(9):119-20.

PMID:
14686309
17.

Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, Maggiolo F, De Luca A, Paraninfo G, Antonucci F, Migliorino G, Lazzarin A, Di Perri G, Rizzardini G, Esposito R, Carosi G.

Infection. 2009 Jun;37(3):244-9. doi: 10.1007/s15010-008-8010-6. Epub 2009 May 26.

PMID:
19471856
18.

Severe atazanavir-associated hyperbilirubinemia revealing Canton G6PD deficiency in an Asian HIV-infected patient.

Javelle E, Oliver M, Savini H, Aubry C, Badens C, Simon F.

AIDS. 2012 Jan 14;26(2):249-51. doi: 10.1097/QAD.0b013e32834e1d33. No abstract available.

PMID:
22179231
19.

Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.

Floridia M, Ravizza M, Masuelli G, Giacomet V, Martinelli P, Degli Antoni A, Spinillo A, Fiscon M, Francisci D, Liuzzi G, Pinnetti C, Marconi AM, Tamburrini E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

J Antimicrob Chemother. 2014 May;69(5):1377-84. doi: 10.1093/jac/dkt497. Epub 2013 Dec 25.

PMID:
24370933
20.

[Evidence-based therapeutic drug monitoring of atazanavir].

Solas C, Muret P; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):213-9. doi: 10.2515/therapie/2011032. Epub 2011 Aug 9. Review. French.

PMID:
21819805

Supplemental Content

Support Center